Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis.

Autor: Mattos WLLD; Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil., Khalil N; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Spencer LG; Aintree Chest Centre, Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom., Bonella F; Center for Interstitial and Rare Lung Disease, Department of Pneumology, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany., Folz RJ; Division of Pulmonary, Critical Care and Sleep Medicine, Houston Methodist Research Institute, Houston, Texas., Rolf JD; Kelowna Respiratory Clinic, Kelowna, British Columbia, Canada., Mogulkoc N; Department of Pulmonary Medicine, Ege University Hospital, Izmir, Turkey., Lancaster LH; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Jenkins RG; Imperial Biomedical Research Center and.; Royal Brompton and Harefield Hospital, London, United Kingdom., Lynch DA; Department of Radiology, National Jewish Health, Denver, Colorado., Noble PW; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California., Maher TM; Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, London, United Kingdom.; Keck School of Medicine, University of Southern California, Los Angeles, California., Cottin V; Department of Respiratory Medicine, Louis Pradel Hospital, Lyon, France.; University Claude Bernard Lyon 1, UMR 754, INRAE, Lyon, France., Senger S; Bristol Myers Squibb, Princeton, New Jersey; and.; Cytel Inc., Waltham, Massachusetts., Horan GS; Bristol Myers Squibb, Princeton, New Jersey; and., Greenberg S; Bristol Myers Squibb, Princeton, New Jersey; and., Popmihajlov Z; Bristol Myers Squibb, Princeton, New Jersey; and.

Publikováno v: American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2024 Aug 15; Vol. 210 (4), pp. 435-443.